GO:0051141 negative regulation of NK T cell proliferation: Immune Checkpoint Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051141 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of natural killer T (NKT) cell proliferation.
• NKT cells are a specialized subset of T lymphocytes that bridge innate and adaptive immunity and can be negatively regulated by NK cells, CD38+CD39+ NK cells, and metabolic factors such as lactic acid.
• Negative regulation of NKT cell proliferation is critical for preventing excessive immune activation, limiting immunopathology, and shaping antitumor and antiviral responses.
• Key molecular players include TIGIT, TET2, SYK, LDHA, and CD38/CD39, which modulate NKT cell expansion through checkpoint inhibition, epigenetic regulation, and metabolic reprogramming.
• Dysregulation of this process is implicated in cancer progression, HIV pathogenesis, graft-versus-host disease, and sepsis, making it a target for immunotherapeutic intervention.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of genes controlling NKT cell proliferation for drug discovery and biomarker development.
Description
Natural killer T (NKT) cells are a unique subset of T lymphocytes that recognize glycolipid antigens presented by CD1d molecules and rapidly produce large amounts of cytokines, bridging innate and adaptive immunity. The proliferation of NKT cells must be tightly controlled to avoid excessive immune activation and tissue damage. GO:0051141, negative regulation of NK T cell proliferation, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of NKT cell proliferation. This regulatory mechanism is essential for maintaining immune homeostasis and preventing autoimmunity, while also influencing outcomes in cancer, infection, and transplantation. Recent studies have identified multiple cellular and molecular players that negatively regulate NKT cell proliferation. NK cells themselves can suppress CD4+ T cell-mediated graft-versus-host disease by limiting NKT cell expansion. CD38+CD39+ NK cells accumulate during HIV infection and negatively regulate T cell proliferation, including NKT cells, through adenosine-mediated pathways. Metabolic factors such as lactic acid produced by LDHA in tumor cells blunt T and NK cell immunosurveillance, indirectly affecting NKT cell proliferation. Checkpoint molecules like TIGIT and signaling regulators such as SYK and TET2 further modulate NKT cell responses. Understanding the negative regulation of NKT cell proliferation is crucial for researchers in immunology, oncology, and infectious disease. This process represents a checkpoint that can be therapeutically targeted to enhance antitumor immunity or to dampen pathological immune activation. The integration of single-cell technologies, CRISPR screens, and functional assays has begun to unravel the complex network of genes and pathways involved.
negative regulation of NK T cell proliferation At A Glance
| GO ID | GO:0051141 |
|---|---|
| GO term | negative regulation of NK T cell proliferation |
| Ontology | biological_process |
| Synonym | down regulation of NK T cell proliferation; inhibition of NK T cell proliferation; negative regulation of natural killer T cell proliferation; negative regulation of NKT cell proliferation |
| Major function | Suppression of NKT cell expansion to maintain immune homeostasis and prevent immunopathology |
| Related cell type | Natural killer T (NKT) cells, a subset of T lymphocytes with innate-like properties |
| Key regulatory molecules | TIGIT, TET2, SYK, LDHA, CD38, CD39, and NK cell-mediated inhibition |
| Associated diseases | Cancer, HIV infection, graft-versus-host disease, sepsis |
| Research methods | CRISPR knockout/knock-in, single-cell RNA sequencing, flow cytometry, functional proliferation assays |
What Is GO:0051141?
GO:0051141, negative regulation of NK T cell proliferation, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer T cell proliferation. This biological process includes mechanisms that inhibit the expansion of NKT cells, a specialized subset of T lymphocytes that express both NK cell markers and a semi-invariant T cell receptor. The term covers both cell-intrinsic and cell-extrinsic regulatory signals, such as checkpoint receptor engagement, cytokine deprivation, metabolic suppression, and contact-dependent inhibition by other immune cells.
Why Is negative regulation of NK T cell proliferation Important in Cell Biology?
Negative regulation of NKT cell proliferation is a critical immune checkpoint that prevents excessive or prolonged immune responses. NKT cells can rapidly produce large amounts of cytokines, and their uncontrolled expansion can lead to tissue damage, autoimmunity, or chronic inflammation. Conversely, insufficient negative regulation can contribute to immunopathology, while excessive suppression can impair antitumor immunity and pathogen clearance. Understanding the molecular mechanisms that restrain NKT cell proliferation is therefore essential for developing therapies that modulate immune responses in cancer, infectious diseases, and transplantation settings.
• Prevents immunopathology by limiting excessive NKT cell expansion and cytokine production.
• Shapes antitumor immunity, as tumor-derived lactic acid and immunosuppressive cells can blunt NKT cell proliferation.
• Influences HIV disease progression through CD38+CD39+ NK cell-mediated suppression of T cell proliferation.
• Modulates graft-versus-host disease severity by regulating NKT cell responses.
• Involved in sepsis outcomes through checkpoint molecules like TIGIT that regulate CD4+ T cell immunity.
• Epigenetic regulators such as TET2 control NKT cell lymphoma progression, linking proliferation control to malignancy.
• SYK acts as a negative regulator of ITAM-mediated NK cell signaling, indirectly affecting NKT cell activation.
• Provides therapeutic targets for enhancing cancer immunotherapy by blocking negative regulators.
• Serves as a biomarker for predicting responses to CDK4/6 inhibitors in breast cancer through immune cell dynamics.
• Enables development of CRISPR-based models to dissect gene function in NKT cell biology.
What Happens During negative regulation of NK T cell proliferation?
Recognition and Checkpoint Engagement
In simple terms: Specialized inhibitory receptors on NKT cells or other immune cells recognize ligands and send 'stop' signals.
Negative regulation of NKT cell proliferation often begins with the engagement of inhibitory receptors such as TIGIT on T cells, which can suppress CD4+ T cell immunity and indirectly limit NKT cell expansion. Similarly, SYK negatively regulates ITAM-mediated signaling in human NK cells, which can impact NKT cell activation and proliferation. These checkpoint interactions provide a first layer of control that prevents excessive NKT cell responses.
Metabolic Suppression
In simple terms: Metabolic byproducts from tumors or other cells can starve or inhibit NKT cells, reducing their ability to multiply.
Lactic acid produced by LDHA in tumor cells blunts tumor immunosurveillance by T and NK cells, and this metabolic suppression extends to NKT cells. The acidic tumor microenvironment impairs NKT cell proliferation and effector functions, representing a key extrinsic negative regulatory mechanism. This metabolic checkpoint is a target for improving cancer immunotherapy.
Cell-Cell Contact and Soluble Mediators
In simple terms: Other immune cells, like NK cells, can directly or indirectly tell NKT cells to stop dividing.
NK cells regulate CD4 T cell-mediated graft-versus-host disease, in part by limiting NKT cell expansion. CD38+CD39+ NK cells, which accumulate during HIV infection, negatively regulate T cell proliferation through adenosine production, affecting NKT cells as well. These contact-dependent and soluble mediator-driven mechanisms provide additional layers of negative regulation.
Epigenetic and Transcriptional Control
In simple terms: Inside the cell, enzymes that modify DNA or histones can switch off genes needed for NKT cell division.
TET2 regulates extranodal NK/T cell lymphoma progression through DNA methylation, and loss of TET2 alters proliferative programs. Epigenetic modifiers such as TET2 can thus influence NKT cell proliferation by changing the expression of growth-promoting genes. This intracellular negative regulation ensures that NKT cells do not divide uncontrollably.
Integration of Signals and Homeostatic Control
In simple terms: The cell integrates all stop signals to decide whether to halt division and maintain balance.
The convergence of checkpoint, metabolic, contact-dependent, and epigenetic signals determines the overall rate of NKT cell proliferation. Single-cell transcriptional studies have revealed dynamic changes in immune cell states, including NKT cells, during disease progression and treatment. This integrated control is essential for immune homeostasis and prevents pathological expansion.
Key Genes Involved in GO:0051141 negative regulation of NK T cell proliferation
The following genes and proteins have been implicated in the negative regulation of NKT cell proliferation or related immune regulatory pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TIGIT | Inhibitory checkpoint receptor that suppresses T cell immunity | Regulates CD4+ T cell responses in sepsis; potential target for immunotherapy |
| TET2 | Epigenetic regulator of DNA methylation | Controls NK/T cell lymphoma progression; loss alters proliferation |
| SYK | Kinase that negatively regulates ITAM-mediated NK cell signaling | Modulates NK cell and potentially NKT cell activation |
| LDHA | Enzyme producing lactic acid | Tumor-derived lactic acid blunts T and NK cell immunosurveillance |
| CD38 | Ectoenzyme involved in adenosine production | Expressed on NK cells that negatively regulate T cell proliferation in HIV |
| CD39 | Ectonucleotidase that generates adenosine | Co-expressed with CD38 on NK cells; suppresses T cell proliferation |
| CD4 | T cell co-receptor | CD4+ T cells mediate GVHD regulated by NK cells |
| CDK4 | Cell cycle kinase | CDK4/6 inhibitors affect immune cell dynamics in breast cancer |
| CDK6 | Cell cycle kinase | CDK4/6 inhibition impacts immune microenvironment |
| HER2 | Receptor tyrosine kinase | HR+/HER2- breast cancer context for immune regulation |
| PD-1 | Inhibitory checkpoint | General T cell exhaustion marker; relevant to NKT cell regulation |
| IFN-gamma | Proinflammatory cytokine | Produced by NKT cells; its regulation is linked to proliferation control |
| IL-4 | Cytokine produced by NKT cells | NKT cell effector cytokine; proliferation affects its levels |
| IL-10 | Anti-inflammatory cytokine | Can suppress T cell proliferation; may affect NKT cells |
| TGF-beta | Immunosuppressive cytokine | Inhibits T cell proliferation; potential role in NKT cell regulation |
| Adenosine | Metabolic signaling molecule | Suppresses T cell proliferation via A2A receptor |
| MHC class I | Antigen presentation molecule | Recognized by inhibitory NK receptors; influences NKT cell regulation |
How Is negative regulation of NK T cell proliferation Regulated?
The negative regulation of NKT cell proliferation is controlled by multiple intersecting pathways. Checkpoint molecules such as TIGIT deliver inhibitory signals that suppress T cell immunity. Metabolic regulators like LDHA and the adenosine pathway (CD38/CD39) create an immunosuppressive microenvironment that restrains NKT cell expansion. Epigenetic enzymes such as TET2 modulate the expression of proliferation-related genes. Additionally, SYK acts as a negative regulator of ITAM-mediated signaling in NK cells, which can indirectly affect NKT cell activation. These pathways are integrated at the cellular level to maintain immune homeostasis and prevent excessive NKT cell responses.
negative regulation of NK T cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDHA | Cancer (tumor immunosurveillance) | LDHA knockout tumor cells co-cultured with NKT cells |
| CD38/CD39 | HIV infection and immune exhaustion | CD38/CD39 double knockout NK cells in HIV models |
| TET2 | NK/T cell lymphoma | TET2 knockout or point mutation in NK/T cell lines |
| TIGIT | Sepsis and inflammatory diseases | TIGIT knockout mice or CAR-T cells |
| SYK | NK cell signaling and immunodeficiency | SYK knockout or point mutation in NK cells |
Cancer and Tumor Immunosurveillance
Negative regulation of NKT cell proliferation contributes to tumor immune evasion. Lactic acid produced by LDHA in tumor cells blunts T and NK cell immunosurveillance, including NKT cells, thereby promoting tumor growth. Single-cell studies in pancreatic ductal adenocarcinoma and breast cancer have revealed immunosuppressive microenvironments that limit NKT cell expansion and function. Targeting these negative regulatory pathways could enhance antitumor immunity.
HIV Infection and Immune Exhaustion
CD38+CD39+ NK cells accumulate during HIV infection and negatively regulate T cell proliferation, including NKT cells, through adenosine-mediated suppression. This contributes to HIV disease progression and immune exhaustion. Understanding this negative regulation may inform immunotherapeutic strategies to restore NKT cell function in HIV patients.
Graft-versus-Host Disease and Transplantation
NK cells regulate CD4 T cell-mediated graft-versus-host disease, in part by controlling NKT cell proliferation. Negative regulation of NKT cell expansion can limit GVHD severity but may also impair graft-versus-leukemia effects. Modulating this balance is a key consideration in hematopoietic stem cell transplantation.
Sepsis and Inflammatory Diseases
TIGIT regulates CD4+ T cell immunity against polymicrobial sepsis, and its inhibitory function may also affect NKT cell proliferation. Excessive negative regulation can lead to immunosuppression and poor sepsis outcomes, while insufficient control can cause cytokine storm. Targeting TIGIT or related pathways could modulate NKT cell responses in sepsis.
From negative regulation of NK T cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X cell-intrinsically suppress NKT cell proliferation? | CRISPR knockout of gene X in primary NKT cells or NKT cell lines |
| Does a specific point mutation in gene Y alter NKT cell proliferation? | CRISPR point mutation knock-in in NKT cells |
| Does overexpression of gene Z inhibit NKT cell expansion? | Lentiviral overexpression in NKT cells |
| How does a tagged version of protein W localize during NKT cell inhibition? | CRISPR knock-in of fluorescent or epitope tag |
| Which genes regulate NKT cell proliferation in a genome-wide manner? | CRISPR library screening in NKT cells |
| What is the transcriptional signature of negatively regulated NKT cells? | Single-cell RNA sequencing of NKT cells from knockout models |
How to Study the negative regulation of NK T cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry with CFSE | Cell division history and proliferation rate | Assessing NKT cell proliferation in vitro |
| Single-cell RNA sequencing | Transcriptional heterogeneity and cell states | Identifying immunosuppressive networks in tumors |
| CRISPR knockout screening | Genes required for or suppressing proliferation | Genome-wide discovery of negative regulators |
| Lactate assay | Lactic acid production | Evaluating metabolic suppression by tumor cells |
| Adenosine detection | Adenosine levels in microenvironment | Measuring CD38/CD39-mediated suppression |
| Western blot | Protein expression and phosphorylation | Validating signaling changes (e.g., SYK, TET2) |
| ELISA | Cytokine production (IFN-gamma, IL-4) | Assessing NKT cell effector function |
| Tetramer staining | NKT cell frequency and antigen specificity | Identifying NKT cells in mixed populations |
Flow Cytometry and Proliferation Assays
Flow cytometry using CFSE or BrdU labeling is the gold standard to measure NKT cell proliferation. Surface markers such as CD1d tetramers identify NKT cells, while intracellular staining for Ki-67 or cytokine production assesses their functional state. These assays can be combined with co-culture systems to test negative regulators.
Single-Cell RNA Sequencing
Single-cell RNA sequencing (scRNA-seq) enables unbiased dissection of NKT cell heterogeneity and transcriptional programs associated with negative regulation. Studies in breast cancer and pancreatic ductal adenocarcinoma have used scRNA-seq to identify immunosuppressive microenvironments and biomarkers predicting treatment response. This method reveals cell-cell communication networks and gene expression changes in NKT cells.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout or activation screens in NKT cell lines or primary cells can identify genes that negatively regulate proliferation. These screens, coupled with next-generation sequencing, pinpoint candidate regulators for validation. Bioinformatics analysis of screen data prioritizes pathways for further study.
Metabolic and Biochemical Assays
Seahorse extracellular flux analysis, lactate measurements, and adenosine detection quantify metabolic suppression of NKT cells. LDHA activity and CD38/CD39 enzymatic function can be assessed to understand how metabolic factors inhibit NKT cell proliferation. These assays complement genetic approaches.
How CRISPR Can Be Used to Study GO:0051141 negative regulation of NK T cell proliferation
Knockout
CRISPR knockout of candidate genes such as TET2, SYK, or CD38 in NKT cell lines or primary cells can determine whether they are required for negative regulation of proliferation. For example, TET2 knockout alters DNA methylation and promotes NK/T cell lymphoma progression, suggesting loss of a negative regulator. SYK knockout enhances ITAM-mediated signaling, confirming its negative regulatory role. These models are essential for causal inference.
Point Mutation
CRISPR point mutation knock-in allows precise modification of specific residues, such as catalytic sites in SYK or TET2, to dissect their function without altering protein levels. This approach can reveal whether enzymatic activity is required for negative regulation of NKT cell proliferation. Point mutations also model human disease variants.
Knock-in
Knock-in of reporter genes (e.g., fluorescent proteins) or epitope tags into endogenous loci enables tracking of NKT cell proliferation and protein localization. Tagged knock-in of TIGIT or CD38 can be used to study their surface expression and interaction partners during negative regulation. This method preserves endogenous regulatory elements.
Overexpression
Overexpression of candidate negative regulators, such as TIGIT or TET2, in NKT cells can test whether increased dosage suppresses proliferation. Lentiviral or CRISPR activation (CRISPRa) systems achieve stable overexpression. This approach is useful for gain-of-function studies and for validating therapeutic targets.
How EDITGENE Supports negative regulation of NK T cell proliferation Research
Researchers studying negative regulation of NK T cell proliferation-related genes often need to determine whether a candidate gene is causally involved in suppressing NKT cell expansion. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation in NKT cells and related immune models, accelerating discovery from target identification to functional validation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of NK T cell proliferation research.
Frequently Asked Questions About negative regulation of NK T cell proliferation
What is GO:0051141?
GO:0051141 is the Gene Ontology term for negative regulation of NK T cell proliferation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer T cell proliferation.
What genes are involved in negative regulation of NK T cell proliferation?
Key genes include TIGIT, TET2, SYK, LDHA, CD38, and CD39, which modulate NKT cell expansion through checkpoint, epigenetic, signaling, and metabolic mechanisms.
How do NK cells negatively regulate NKT cell proliferation?
NK cells can suppress NKT cell expansion through contact-dependent mechanisms and soluble mediators, as shown in graft-versus-host disease and HIV models.
What diseases are associated with dysregulated NKT cell proliferation?
Cancer, HIV infection, graft-versus-host disease, and sepsis are linked to altered negative regulation of NKT cell proliferation.
How can I study negative regulation of NKT cell proliferation in the lab?
Common methods include flow cytometry proliferation assays, single-cell RNA sequencing, CRISPR knockout screens, and metabolic assays.
What is the role of TET2 in NKT cell proliferation?
TET2 regulates DNA methylation and its loss promotes NK/T cell lymphoma progression, suggesting it acts as a negative regulator of proliferation.
Does lactic acid affect NKT cell proliferation?
Yes, LDHA-derived lactic acid in the tumor microenvironment blunts T and NK cell immunosurveillance, including NKT cells.
What is the connection between CD38/CD39 and NKT cells?
CD38+CD39+ NK cells negatively regulate T cell proliferation, including NKT cells, via adenosine production during HIV infection.
Can CRISPR be used to study negative regulation of NKT cell proliferation?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise genetic dissection of regulators in NKT cells.
What are the therapeutic implications of targeting negative regulators of NKT cell proliferation?
Blocking negative regulators like TIGIT or LDHA could enhance antitumor immunity, while enhancing them might treat autoimmune or inflammatory diseases.
Conclusion
Negative regulation of NK T cell proliferation (GO:0051141) is a vital immune checkpoint that prevents excessive NKT cell expansion and maintains immune homeostasis. Dysregulation of this process contributes to cancer, HIV progression, graft-versus-host disease, and sepsis. Key molecular players such as TIGIT, TET2, SYK, LDHA, and CD38/CD39 provide promising targets for therapeutic intervention. Advances in CRISPR gene editing, single-cell sequencing, and functional genomics are accelerating our understanding of this process. EDITGENE offers comprehensive services to support researchers in dissecting the genetic and molecular mechanisms of NKT cell regulation, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Luo L et al.. 2025. Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer.. Mol Cancer 24(1):48 PMID: 39955556
- 2. Brand A et al.. 2016. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.. Cell Metab 24(5):657-671 PMID: 27641098
- 3. Xiang C et al.. 2024. TET2 regulates extranodal NK/T cell lymphoma progression through regulation of DNA methylation.. Hematol Oncol 42(4):e3295 PMID: 38979860
- 4. Liu X et al.. 2025. Single-cell transcriptional dissection illuminates an evolution of immunosuppressive microenvironment during pancreatic ductal adenocarcinoma metastasis.. Signal Transduct Target Ther 10(1):182 PMID: 40484878
- 5. Zhong X et al.. 2024. TIGIT regulates CD4(+) T cell immunity against polymicrobial sepsis.. Front Immunol 15:1290564 PMID: 38545097
- 6. Noval Rivas M et al.. 2010. NK cell regulation of CD4 T cell-mediated graft-versus-host disease.. J Immunol 184(12):6790-8 PMID: 20488796
- 7. Qian S et al.. 2022. CD38(+)CD39(+) NK cells associate with HIV disease progression and negatively regulate T cell proliferation.. Front Immunol 13:946871 PMID: 36268017
- 8. Millan AJ et al.. 2025. SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy.. J Immunol 214(3):384-398 PMID: 40073103
